Alembic gets USFDA tentative nod for cancer drug

Alembic gets USFDA tentative nod for cancer drug Alembic Pharmaceuticals received tentative approval from the USFDA for its Larotrectinib Capsules, a generic version of Vitrakvi. The drug is used for treating NTRK gene fusion-positive cancers. Tentative approval means the product meets quality standards but cannot be launched until patent expiry. Final approval and market entry depend on intellectual property timelines.

📊 STOCKS: APLLTD | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #USFDA